05Mar 2023
Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial

Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial

A phase I/II clinical trial of a new COVID-19 vaccine called "Betuvax-CoV-2" has been conducted, which is a recombinant protein subunit vaccine based on the S-protein RBD fused with the Fc-fragment of IgG. The trial involved 116 healthy adult men and women, ages 18-58, who were given different doses of the vaccine or a placebo, and the safety and immunogenicity of the vaccine were evaluated. The results showed that the vaccine was safe and well-tolerated, and induced a strong humoral response. The authors conclude that further research is needed to determine the protective effectiveness of the vaccine for the prevention of COVID-19.

  • #family health

Like

Save

Share